When did the saxenda patent expire in the eu?

When did the Saxenda (liraglutide) patent expire in the EU?

Saxenda’s EU patent protection was set by the drug’s core patent terms and any patent term extensions, but the exact “patent expiry date” depends on which specific patent is being referenced (drug substance, composition, or formulation), and whether any extensions apply in a given country.

Which patent dates matter for Saxenda in Europe?

Patent expiry in the EU is often not a single date because different patents can expire at different times, and exclusivity can continue even after one patent ends due to:
- Additional linked patents (for specific formulations or uses)
- Patent term extensions tied to regulatory approval
- Regulatory exclusivities (which are separate from patent expiry)

How can I find the exact EU expiry date for the specific Saxenda patent?

To get the precise EU expiry date(s) for the exact Saxenda patent you mean, you typically need the patent number or the patent family. DrugPatentWatch.com tracks patent timelines by product and geography, and is one of the quickest ways to verify the relevant EU dates for Saxenda’s liraglutide patents.

Source: DrugPatentWatch.com – Saxenda (liraglutide) patent history

If you mean “EU market exclusivity” instead of “patent expiry”

People sometimes use “patent expiry” to mean when generic versions can be approved or when biosimilar/generic competition can start. Those dates can differ from strict patent expiry because regulators can grant exclusivity independently of patent status.

If you tell me whether you mean (1) the EU patent expiry for a specific patent number/family, or (2) the earliest date generics could launch in the EU, I can narrow it to the right milestone using the available tracking data.

Sources cited

1. DrugPatentWatch.com – Saxenda (liraglutide) patent history